At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 09 Dec 1999 Discontinued-II for Benign prostatic hyperplasia in European Union (Unknown route)
- 31 Jul 1997 Suspended-II for Benign prostatic hyperplasia in European Union (Unknown route)
- 01 Jul 1996 Phase-II clinical trials for Benign prostatic hyperplasia in European Union (Unknown route)